Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 5 (A) Levels of activated nuclear factor kappa B (specific Trans-AM p50 and p65 subunit assay kit) and inhibitory kappa B (IkB)-beta asymptomatic, placebo-treated, and rosiglitazone-treated symptomatic plaques; (B) immunohistochemistry for activated p65 (x630) and p50 (x630) and IkB-beta (x800). Similar regions of the plaque are shown. These results are typical of asymptomatic, placebo-treated, and rosiglitazone-treated symptomatic plaques. *p < 0.05 compared with placebo group.  p < 0.05 compared with rosiglitazone group.
|
